Viva Biotech HoldingsVBIZF 49 Market Cap is $320.2 Mil as of Jul. 11, 2026. GuruFocus rates VBIZF with a GF Score™ of 49/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,422 Biotechnology companies, Viva Biotech Holdings ranks better than 64.42% on this metric.
Viva Biotech Holdings's quarterly market cap
increased
from Dec. 2024 ($149.8 Mil) to Jun. 2025 ($510.5 Mil) but then
declined
from Jun. 2025 ($510.5 Mil) to Dec. 2025 ($409.3 Mil).
Viva Biotech Holdings's annual market cap
declined
from Dec. 2023 ($264.3 Mil) to Dec. 2024 ($149.8 Mil) but then
increased
from Dec. 2024 ($149.8 Mil) to Dec. 2025 ($409.3 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Viva Biotech Holdings's Enterprise Value for Today is $354.5 Mil.
Viva Biotech Holdings (OTCPK:VBIZF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Viva Biotech Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Viva Biotech Holdings's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viva Biotech Holdings (VBIZF) has a Market Cap of $320.2 Mil as of Jul. 11, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Viva Biotech Holdings and its competitors. According to the industry distribution chart, Viva Biotech Holdings ranks #506 out of 1422 companies in the Biotechnology industry, placing it in the top 35.6%.
Is Viva Biotech Holdings' Market Cap too high?
Viva Biotech Holdings' current Market Cap is $320.2 Mil. The Biotechnology industry median Market Cap is 120.54. Viva Biotech Holdings' value of $320.2 Mil is 165.6% above this industry median. Based on the distribution chart, Viva Biotech Holdings ranks #506 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Viva Biotech Holdings has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #506 out of 1422 companies for Market Cap. This puts Viva Biotech Holdings in the upper half of its industry. The industry median Market Cap is 120.54. Viva Biotech Holdings' value of $320.2 Mil is 165.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 120.54, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viva Biotech Holdings's current Market Cap of $320.2 Mil is 165.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Viva Biotech Holdings and its competitors. For the Biotechnology industry, the median Market Cap is 120.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viva Biotech Holdings's current Market Cap is $320.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (VBIZF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.16 — trading 101.9% above its estimated fair value. The current Market Cap is $320.2 Mil and 165.6% above the Biotechnology industry median of 120.54. Viva Biotech Holdings' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Viva Biotech Holdings (VBIZF), the current Market Cap is $320.2 Mil as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (VBIZF) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of $0.16 is trading 101.9% above its estimated GF Value™ of $0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for VBIZF:
Market Cap: $320.2 Mil
GF Value™: $0.08 vs. price of $0.16 (101.9% above fair value)
Industry Position: 165.6% above the Biotechnology median (#506 of 1422)
No single metric tells the full story. See the VBIZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
49GF Score
Get the complete analysis for VBIZF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VBIZF has been successfully added to your 
